siltuximab + dexamethasone

A **combination therapy** of the chimeric monoclonal antibody siltuximab and the synthetic glucocorticoid corticosteroid dexamethasone. Siltuximab is a monoclonal antibody that specifically binds and neutralizes interleukin-6 (IL-6), thereby inhibiting IL-6-mediated pro-inflammatory and proliferative effects. Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant effects that acts by binding to and activating the glucocorticoid receptor, thereby downregulating inflammatory and immune responses. This combination has been used in clinical research and real-world settings, notably in refractory or relapsed multiple myeloma and idiopathic multicentric Castleman disease (iMCD), particularly when a more robust anti-inflammatory or anti-neoplastic effect is desired. The combination increases response rates compared with siltuximab monotherapy and is considered when corticosteroid pre-treatment or augmentation is needed in certain hematological disorders[4][6].